Lupus Research Alliance Awards Lupus Insight Prize to Two Trailblazers in CAR T Cell Therapy
The Lupus Research Alliance (LRA) announced the recipients of the 2024 Lupus Insight Prize to Marko Radic, Ph.D., The University of Tennessee Health Science Center, and Georg Schett, M.D., Friedrich-Alexander-Universität Erlangen-Nürnberg, for their groundbreaking discoveries in utilizing CAR T cell therapy to potentially revolutionize lupus treatment. Drs. Radic and Schett were honored at a celebratory […]
Lupus Research Alliance Announces Four New Recipients of the Lupus Mechanisms and Targets Award
Winning projects will explore new potential treatment approaches to prevent lupus from developing or prevent or slow disease progression. NEW YORK, NY, April 20, 2023. The Lupus Research Alliance (LRA) today announced the newest Lupus Mechanisms and Targets Award grant recipients. The winning four projects collectively test potential treatment approaches to prevent lupus from developing […]
Lupus Research Alliance Announces Recipients of 2023 Diversity in Lupus Research Awards
NEW YORK, NY, July 12, 2023 — The Lupus Research Alliance is pleased to announce the 2023 recipients of the Career Development and Postdoctoral Awards to Promote Diversity in Lupus Research. The Diversity in Lupus Research Awards aim to foster the development of outstanding, underrepresented minority scientists and establish a diverse community of researchers and […]
Lupus Research Alliance Announces Recipients of 2024 Diversity in Lupus Research Awards
The Lupus Research Alliance (LRA) is pleased to announce the recipients of the 2024 Career Development and Postdoctoral Awards to Promote Diversity in Lupus Research. Launched in 2021, the Diversity in Lupus Research (DLR) Awards aim to foster the development and productivity of exceptional early-career and postdoctoral scientists from underrepresented minority groups in science. Lupus […]
LRA Highlights Full Continuum of Lupus Research at ACR Convergence 2020
30+ presentations of studies funded by the Lupus Research Alliance on a variety of immune pathways Results from three clinical studies conducted in part by LRA-affiliate Lupus Therapeutics (LT) through its trials network 10 lupus presentations by the Accelerating Medicines Partnership Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE) program (AMP RA/SLE) NEW YORK, NY, […]
How Are the New Lupus Nephritis Guidelines Impacting Treatment?
Recognized as National Kidney Month, March is the ideal time to learn more about the 2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis. Recently issued, the guidelines are designed to provide healthcare providers with up-to-date guidance on the care and treatment of adults and children with lupus […]
LRA Statement: Potential Lupus Nephritis Drug Voclosporin Granted Priority Review by the U.S. FDA
NEW YORK, NY. July 22, 2020. The Lupus Research Alliance congratulates Aurinia Pharmaceuticals Inc. on acceptance of its NDA filing and priority review designation by the U.S. Food and Drug Administration for its investigational drug voclosporin for lupus nephritis. A serious inflammation of the kidneys, lupus nephritis is one of the most common complications of […]
Low-Dose Chemotherapy May Help Lupus Nephritis
February 22, 2021 In a recent study published in Arthritis & Rheumatology, LRA-funded researcher Dr. Xian Zhang found that a low dose of the chemotherapy drug topotecan reduced the inflammation and kidney damage of lupus nephritis in mice with lupus. Topotecan was as effective as high doses of cyclophosphamide, another chemotherapy that’s currently used to […]
LRA Highlights Groundbreaking Lupus Research at ACR Convergence 2023
This information is brought to you by the Lupus Research Alliance and Lupus Therapeutics and is not sponsored by, nor a part of, the American College of Rheumatology. 30+ presentations of studies funded by the LRA spanning a broad spectrum of research areas Positive results from Phase 2/3 clinical studies supported by LRA affiliate Lupus Therapeutics point to […]
Reducing B Cells with Modified CAR T Cells is an Effective Treatment of Experimental Lupus: Shows Study Supported by Lupus Research Alliance
NEW YORK, NY. March 6, 2019. Depleting the number of harmful B cells with a novel immunotherapy that employs modified T cells may offer an effective strategy to treat lupus, according to a new study funded by the Lupus Research Alliance. These findings offer a renewed optimism for the elimination of B cells to provide […]
LRA Congratulates GSK on FDA Approval of Benlysta® (belimumab) for Children with Lupus Nephritis
NEW YORK, NY. July 27, 2022. The Lupus Research Alliance (LRA) is pleased to share that the U.S. Food and Drug Administration (FDA) has approved belimumab (Benlysta®) as the first-ever treatment specifically indicated for children aged 5 to 17 with lupus nephritis. Belimumab is already approved by the FDA to treat lupus nephritis in adults […]
Lupus Research Alliance Hails Approval of Aurinia’s Lupkynis(TM) (voclosoporin)
First Oral Treatment for Lupus Nephritis; Second Lupus Treatment to Receive FDA Approval in Past Month NEW YORK, NY. January 22, 2021. The Lupus Research Alliance (LRA) is excited to share that the U.S. Food and Drug Administration (FDA) approved the use of Aurinia Pharmaceuticals’ LupkynisTM (voclosporin) as the first oral treatment developed specifically for […]